Repeated clinical success drove shares of GW Pharmaceuticals (NASDAQ: GWPH) about 60% higher in 2016, and an impressive 190% higher than low points in March. If you missed the boat last year, you’ll be happy to know there are at least three reasons this top marijuana stock could continue rising in the new year and beyond.
Continue Reading Below
Image source: Getty Images.
1. Four in a row?
In 2016, GW Pharmaceuticals notched three late-stage clinical trial successes with its cannabidiol candidate Epidiolex for treatment of different forms of epilepsy.
Two particularly interesting phase 3 Epidiolex trials were for treatment of Lennox-Gastaut syndrome (LGS), a childhood-onset